ES2583032T3 - Péptidos con actividad apoptótica - Google Patents
Péptidos con actividad apoptótica Download PDFInfo
- Publication number
- ES2583032T3 ES2583032T3 ES10010931.3T ES10010931T ES2583032T3 ES 2583032 T3 ES2583032 T3 ES 2583032T3 ES 10010931 T ES10010931 T ES 10010931T ES 2583032 T3 ES2583032 T3 ES 2583032T3
- Authority
- ES
- Spain
- Prior art keywords
- val
- tyr
- arg
- met
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 7
- 230000001640 apoptogenic effect Effects 0.000 title description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000684 flow cytometry Methods 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000000411 inducer Substances 0.000 abstract 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 abstract 1
- 239000000158 apoptosis inhibitor Substances 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 210000003606 umbilical vein Anatomy 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sustancia de actividad apoptótica, caracterizada por que comprende al menos una porción peptídica con una de las secuencias de aminoácidos representadas en las SEQ ID nºs 12, 18 y 19 e induce la apoptosis.
Description
Naturales y Médico de la Universidad de Tübingen, Reutlingen, Alemania).
EJEMPLO 5: Identificación de péptidos hexámeros de actividad apoptótica con ayuda del procedimiento de acuerdo con la invención
Las células se cultivan como se describe en el Ejemplo 1. Las células se siembran en los respectivos recipientes de 5 cultivo (p. ej. placa de 24 pocillos/0,5 ml por cavidad) y, tras alcanzar la confluencia completa, se emplean para el ensayo. Las células se abastecen con medio nuevo:
- (a)
- Medio de cultivo reciente [tasa base de la apoptosis],
- (b)
- Medio reciente con 1 µg/ml de TSP-1 [sustancia inductora dela apoptosis; control],
(1) Medio (b) + péptido de SEQ ID NO: 12, 1 mM 10 (r) Medio (b) + péptido de SEQ ID NO: 18, 1 mM
(s) Medio (b) + péptido de SEQ ID NO: 19, 1 mM
Después de 24 h de incubación bajo condiciones de cultivo (Ejemplo 1) se fijan las células, se tiñen con DAPI y se examinan morfológicamente bajo el microscopio de fluorescencia o se examinan por citometría de flujo. Se determinan las células apoptóticas y el número total de células y se calcula el índice de la apoptosis (porcentaje de
15 células apoptóticas). En la Tabla 2 se indican los datos de 3 experimentos independientes con el dato de los valores medios y la desviación estándar. Péptidos de acción inhibidora presentan, de acuerdo con la invención, un índice de inhibición positivo, mientras que péptidos inductores presentan, de acuerdo con la invención, un índice de inhibición negativo.
Tabla 2: Se sometieron a ensayo los siguientes péptidos:
- SEQ ID NO
- Secuencia de aminoácidos Índice de la apoptosis [%] Índice de inhibición [%]*
- K
- Control 3,28 ± 0,55
- (12)
- M-V-V-Y-F-R 4,40 ± 0,53 -34,1 ± 6,2
- (18)
- m-v-v-y-f-r 14,6 ± 0,75 -345,1 ± 5,1
- (19)
- m-v-v-y-a-r 11,4 ± 0,63 -247,1 ± 5,4
- *índice de inhibición positivo = sustancia inhibida; índice de inhibición negativo = sustancia inducida
De acuerdo con la invención, el índice de inhibición se calcula como sigue: -índice de inhibición [%] = (índice de apoptosis medido · 100/control del índice de apoptosis) -100
8
Claims (1)
-
imagen1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10163130A DE10163130B4 (de) | 2001-12-20 | 2001-12-20 | Apoptotisch wirksame Peptide und diese umfassende pharmazeutische Zusammensetzungen |
| DE10163130 | 2001-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2583032T3 true ES2583032T3 (es) | 2016-09-16 |
Family
ID=7710281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02805332T Expired - Lifetime ES2369883T3 (es) | 2001-12-20 | 2002-12-18 | Péptidos con actividad apoptótica. |
| ES10010931.3T Expired - Lifetime ES2583032T3 (es) | 2001-12-20 | 2002-12-18 | Péptidos con actividad apoptótica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02805332T Expired - Lifetime ES2369883T3 (es) | 2001-12-20 | 2002-12-18 | Péptidos con actividad apoptótica. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7892556B2 (es) |
| EP (2) | EP2332964B1 (es) |
| JP (1) | JP4384494B2 (es) |
| AT (1) | ATE517117T1 (es) |
| AU (1) | AU2002366739A1 (es) |
| DE (1) | DE10163130B4 (es) |
| ES (2) | ES2369883T3 (es) |
| WO (1) | WO2003054009A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10358407A1 (de) | 2003-12-11 | 2005-07-14 | Cytotools Gmbh | Antiapoptorisch wirksame Aptamere (zur Therapie von Herz-Kreislauf Erkrankungen) |
| WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| WO2020234239A1 (en) | 2019-05-22 | 2020-11-26 | Cytopharma Gmbh | A pharmaceutically active substance |
| JP2022540731A (ja) * | 2019-07-12 | 2022-09-16 | オーピー－ティー エルエルシー | ペプチドおよび疾患の治療方法 |
| EP4135742A2 (en) | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668503A (en) | 1982-07-26 | 1987-05-26 | Trustees Of University Of Massachusetts | Process for labeling amines with 99m Tc |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4652440A (en) | 1984-05-03 | 1987-03-24 | Paik Chang H | Method of stably radiolabeling antibodies with technetium and rhenium |
| US5627265A (en) | 1993-03-05 | 1997-05-06 | Washington University | Receptor for cell-binding domain of thrombospondins |
| US5399667A (en) * | 1993-03-05 | 1995-03-21 | Washington University | Thrombospondin receptor binding peptides |
| AUPM885894A0 (en) | 1994-10-18 | 1994-11-10 | University Of Newcastle Research Associates Limited, The | Therapeutic molecules |
| US5627048A (en) * | 1994-11-04 | 1997-05-06 | Research Corporation Technologies, Inc. | Aedes aegypti densovirus expression system |
| US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| IL129222A0 (en) * | 1996-10-01 | 2000-02-17 | Geron Corp | Telomerase reverse transcriptase |
| WO1998058541A1 (en) * | 1997-06-24 | 1998-12-30 | Dana-Farber Cancer Institute, Inc. | Modulation of apoptosis |
| FR2777890B1 (fr) * | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
| WO2000047102A2 (en) | 1999-02-11 | 2000-08-17 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
-
2001
- 2001-12-20 DE DE10163130A patent/DE10163130B4/de not_active Expired - Lifetime
-
2002
- 2002-12-18 EP EP10010931.3A patent/EP2332964B1/de not_active Expired - Lifetime
- 2002-12-18 EP EP02805332A patent/EP1458748B1/de not_active Expired - Lifetime
- 2002-12-18 ES ES02805332T patent/ES2369883T3/es not_active Expired - Lifetime
- 2002-12-18 WO PCT/EP2002/014439 patent/WO2003054009A2/de not_active Ceased
- 2002-12-18 JP JP2003554725A patent/JP4384494B2/ja not_active Expired - Fee Related
- 2002-12-18 ES ES10010931.3T patent/ES2583032T3/es not_active Expired - Lifetime
- 2002-12-18 US US10/499,930 patent/US7892556B2/en not_active Expired - Fee Related
- 2002-12-18 AT AT02805332T patent/ATE517117T1/de active
- 2002-12-18 AU AU2002366739A patent/AU2002366739A1/en not_active Abandoned
-
2010
- 2010-12-23 US US12/977,672 patent/US9017693B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003054009A2 (de) | 2003-07-03 |
| EP2332964B1 (de) | 2016-04-20 |
| AU2002366739A1 (en) | 2003-07-09 |
| JP4384494B2 (ja) | 2009-12-16 |
| JP2005526013A (ja) | 2005-09-02 |
| EP2332964A1 (de) | 2011-06-15 |
| US20110178000A1 (en) | 2011-07-21 |
| US9017693B2 (en) | 2015-04-28 |
| EP1458748A2 (de) | 2004-09-22 |
| ES2369883T3 (es) | 2011-12-07 |
| DE10163130A1 (de) | 2003-07-10 |
| ATE517117T1 (de) | 2011-08-15 |
| EP1458748B1 (de) | 2011-07-20 |
| WO2003054009A3 (de) | 2003-11-06 |
| US7892556B2 (en) | 2011-02-22 |
| DE10163130B4 (de) | 2009-05-14 |
| AU2002366739A8 (en) | 2003-07-09 |
| US20050222020A1 (en) | 2005-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes | |
| Zhou et al. | Myofiber necroptosis promotes muscle stem cell proliferation via releasing Tenascin-C during regeneration | |
| Zhang et al. | Extremely low frequency electromagnetic fields promote mesenchymal stem cell migration by increasing intracellular Ca2+ and activating the FAK/Rho GTPases signaling pathways in vitro | |
| Tian et al. | Bone morphogenetic protein‐2 promotes osteosarcoma growth by promoting epithelial‐mesenchymal transition (EMT) through the Wnt/β‐catenin signaling pathway | |
| Zhao et al. | Autophagy regulates hypoxia‐induced osteoclastogenesis through the HIF‐1α/BNIP3 signaling pathway | |
| Currie et al. | Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma | |
| Xu et al. | Bisphenol A promotes dendritic morphogenesis of hippocampal neurons through estrogen receptor-mediated ERK1/2 signal pathway | |
| Liebermann et al. | Gadd45 in the response of hematopoietic cells to genotoxic stress | |
| Gifford et al. | Notch1 and Notch2 receptors regulate mouse and human gastric antral epithelial cell homoeostasis | |
| ES2583032T3 (es) | Péptidos con actividad apoptótica | |
| Li et al. | Mangiferin Prevents TBHP‐Induced Apoptosis and ECM Degradation in Mouse Osteoarthritic Chondrocytes via Restoring Autophagy and Ameliorates Murine Osteoarthritis | |
| Hou et al. | C1q tumor necrosis factor-related protein-3 protects mesenchymal stem cells against hypoxia-and serum deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway | |
| Ye et al. | The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway | |
| Cui et al. | Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells | |
| Schnoke et al. | Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair | |
| Huang et al. | Activation of the bile acid receptor GPBAR1 (TGR5) ameliorates interleukin-1β (IL-1β)-induced chondrocytes senescence | |
| Liu et al. | Caspase‐3‐mediated cyclic stretch‐induced myoblast apoptosis via a Fas/FasL‐independent signaling pathway during myogenesis | |
| Cherng et al. | Apoptotic insults to human chondrocytes induced by sodium nitroprusside are involved in sequential events, including cytoskeletal remodeling, phosphorylation of mitogen‐activated protein kinase kinase kinase‐1/c‐Jun N‐terminal kinase, and Bax‐Mitochondria‐Mediated caspase activation | |
| Ayachi et al. | The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival | |
| Zhang et al. | SDF1/CXCR4 axis facilitates the angiogenesis via activating the PI3K/AKT pathway in degenerated discs | |
| Li et al. | Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition | |
| Jung et al. | Aqueous extract of Psoralea corylifolia L. inhibits lipopolysaccharide-induced endothelial-mesenchymal transition via downregulation of the NF-κB-SNAIL signaling pathway | |
| Suzuki et al. | Bcl-2 accelerates the neuronal differentiation: new evidence approaching to the biofunction of bcl-2 in the neuronal system | |
| Yan et al. | Mechanical stress‐induced IGF‐1 facilitates col‐I and col‐III synthesis via the IGF‐1R/AKT/mTORC1 signaling pathway | |
| Dickson et al. | Hoxa6 potentiates short-term hemopoietic cell proliferation and extended self-renewal |